Immunomodulatory drugs such as thalidomide and its derivatives, such as lenalidomide and pomalidomide, are among the most recognized synthetic molecular glue degraders (MGDs) approved for the treatment of multiple myeloma, AML, and other hematological diseases.314,382 They bind the cereblon protein (CRBN), which, along with Cullin4A (cul4) and damage-specific DNA-binding protein 1 (DDB1), forms the Cullin RING Ligase 4 (CRL4) complex, which is responsible for protein degradation. Here, CRBN is linked to plasma cell myeloma.